Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

Lancet

Volumn 347, Issue 9005, 1996, Pages 849-853

  Ericsson, Carl Göran ^a   Hamsten, Anders ^b   Nilsson, Jan ^b   Grip, Lars ^b   Svane, Bertil ^b   De Faire, Ulf ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIET THERAPY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029982038     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91343-4     Document Type: Article

References (27)

1. Bergstrand R, Vedin A, Wilhelmsson C, Wilhelmsen L. Incidence and prognosis of acute myocardial infarction among men below 40 in Göteborg, Sweden. Eur Heart J 1982; 3: 130.
2. Malmberg K, Bavenholm P, Hamsten A. Clinical and biochemical factors associated with the prognosis after myocardial infarction at a young age. J Am Coll Cardiol 1994; 24: 592-99.
3. Hamsten A, Walldius G, Dahlén G, Johansson B, de Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986; 59: 223-35.
4. Hamsten A, Efendic S, Walldius G, Szamosi A, de Faire U. Glucose tolerance and insulin response to glucose in non-diabetic young male survivors of myocardial infarction. Am Heart J 1987; 113: 917-27.
5. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young male survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
6. Hamsten A, de Faire U. Risk factors for coronary artery disease in families of young men with myocardial infarction. Am J Cardiol 1987; 59: 14-19.
7. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis 1991; 90: 67-80.
8. Hamsten A, Blombäck M, Wiman B, et al. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66.
9. Monk JP, Todd PA. Bezafibrate: a review of its pharmacological and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 1987; 33: 539-76.
10. Ståhberg D. Effects of bezafibrate: a hypolipidaemic drug. Cardiovasc Drug Rev 1992; 10: 259-79.
11. de Faire U, Ericsson C-G, Hamsten A, Nilsson J, for the Bezafibrate Coronary Atherosclerosis Intervention Trial Investigators. Design features of a five-year bezafibrate coronary atherosclerosis intervention trial. Drugs Exptl Clin Res 1995; XXI: 105-24.
12. Reiber JHC, Serruys PW. Quantitative coronary angiography. Developments in cardiovascular medicine. Dordrecht: Kluwer Academic Publishers, 1991.
13. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Circulation 1975; 51: 5-40.
14. Jukema JE, Bruschke AVG, van Boven AJ, et al, on behalf of the REGRESS Study Group. Effect of lipid lowering by pravastatin on progression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.
15. MAAS investigators. Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet 1994; 344: 633-38.
16. Brensike JF, Levy RI, Kelset S, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of NHLI type II coronary intervention study. Circulation 1984; 69: 313-24.
17. Lehmann EL. Testing Statistical Hypothesis. New York: Wiley, 1986.
18. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoproteins subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994; 5: 395-403.
19. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995; 6: 209-14.
20. Blankenhorn DH, Azen SP, Kramsch DM, et al, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119: 969-76.
21. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assesssed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90: 42-49.
22. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995; 322: 512-21.
23. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
24. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-59.
25. Thompson SG, Kienaast J, Pyke SDM, Haverkarf F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
26. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
27. Goldbourt U, Behar S, Reicher-Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993; 71: 909-14.